Trial Profile
A retrospective, observational study to investigate molecular response in patients with chronic Myelogenous Leukemia treated with Nilotinib versus Dasatinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Dasatinib
- Indications Myeloid leukaemia
- Focus Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association